Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Public ClinicalTrials.gov record NCT04681105. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the best dose and side effects of flotetuzumab for the treatment of patients with blood cancers (hematological malignancies) that have spread to other places in the body (advanced) and have come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Flotetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Study identification
- NCT ID
- NCT04681105
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 13 participants
Conditions and interventions
Conditions
- Recurrent Acute Leukemia
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Hairy Cell Leukemia
- Recurrent Hematologic Malignancy
- Recurrent Hodgkin Lymphoma
- Recurrent T Acute Lymphoblastic Leukemia
- Refractory Acute Leukemia
- Refractory B Acute Lymphoblastic Leukemia
- Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Refractory Hairy Cell Leukemia
- Refractory Hematologic Malignancy
- Refractory Hodgkin Lymphoma
- Refractory T Acute Lymphoblastic Leukemia
- Systemic Mastocytosis
Interventions
- Acetaminophen Drug
- Dexamethasone Drug
- Diphenhydramine Drug
- Flotetuzumab Biological
- Ibuprofen Drug
- Ranitidine Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 17, 2020
- Primary completion
- Aug 4, 2025
- Completion
- Aug 4, 2025
- Last update posted
- Jan 27, 2026
2020 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04681105, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 27, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04681105 live on ClinicalTrials.gov.